Division of Gastroenterology, Department of Internal Medicine, University Hospital Rijeka, Krešimirova 42, Rijeka 51000, Croatia.
Obes Surg. 2011 May;21(5):551-5. doi: 10.1007/s11695-010-0310-0.
The intragastric balloon is a widely used method in the treatment of obesity indicated for those patients who have failed to achieve and maintain the weight loss with conventional measures or for preparation of patients who are candidates for bariatric surgery.
From April 2007 to April 2009, 171 consecutive patients (111 females, 60 males; mean age 39.2 ± 10.5, mean weight 123.2 ± 27.1 kg) were evaluated before and 6 months after bioenteric intragastric balloon (BIB) placement by assessment of anthropometric and biochemical parameters.
The mean BMI during balloon treatment declined from 41.9 ± 7.3 to 36.0 ± 7.9 kg/m² (p < 0.001) with a percentage of excess weight loss of 39.7 ± 23.6 and percentage of excess body mass index loss of 39.5 ± 25.1. A significant improvement in blood pressure, glycemia, and triglyceride level but not in total cholesterol, high-density lipoprotein, and low-density lipoprotein cholesterol levels was seen.
Results of this large prospective single center study confirmed that intragastric balloon is useful and safe method for promoting weight loss. Due to improvement of metabolic parameters, treatment with BIB results in reduction of cardiovascular risk and provides a sustained benefit on liver function in obese patients.
胃内球囊是一种广泛应用于肥胖症治疗的方法，适用于那些通过常规措施未能达到并维持体重减轻的患者，或用于准备接受减重手术的患者。
从 2007 年 4 月至 2009 年 4 月，171 例连续患者（111 例女性，60 例男性；平均年龄 39.2±10.5 岁，平均体重 123.2±27.1 公斤）在接受生物可吸收胃内球囊（BIB）置入前后通过评估人体测量和生化参数进行评估。
在球囊治疗期间，平均 BMI 从 41.9±7.3 下降到 36.0±7.9 kg/m²（p<0.001），体重减轻率为 39.7±23.6%，体重指数减轻率为 39.5±25.1%。血压、血糖和甘油三酯水平显著改善，但总胆固醇、高密度脂蛋白和低密度脂蛋白胆固醇水平没有改善。
这项大型前瞻性单中心研究的结果证实，胃内球囊是促进体重减轻的有用且安全的方法。由于代谢参数的改善，BIB 治疗可降低心血管风险，并为肥胖患者的肝功能提供持续获益。
